Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Oct 26 - Oct 31
Review published records below or browse the COA Library
A review on Alzheimer's disease pathophysiology and its management: an update
doi: 10.1001/jamainternmed.2025.1133 55 Bagherzadeh-RahmaniBMarzettiEKaramiECampbellBIFakourianAHaghighiAHet al
Results showed that GLP-1 receptor agonists and SGLT2 inhibitors were superior in reducing the risk of MACE when compared to DPP-4 inhibitors (HR 086 [082089] and 086 [082090], respectively), but no difference was found between SGLT2 inhibitors and GLP-1 receptor agonists in reducing rate of MACE (HR of 101 (094107)) ( Conclusion In conclusion, CVOTs have played a pivotal role in evaluating the cardiovascular safety and efficacy of GLP-1 receptor agonists in patients with T2D
Providers should ask specifically whether semaglutide is compounded from the base form or a salt form (semaglutide sodium, semaglutide acetate) the FDA has identified salt forms as distinct active ingredients from the approved base form
The 56-week estimand was assumed equal to the 52-week estimand required for modelling
